Sociedad Americana de Hirudoterapia

Does anticoagulation improve outcomes of microvascular free flap reconstruction following head and neck surgery: a systematic review and meta-analysis.

Review published in The British journal of oral & maxillofacial surgery (2022)

Última actualización: 18 de junio de 2026Revisado por: ASH Editorial Board
Artículo de investigación — revisión de evidenciaReferencia del artículo
Evidence: Meta-analysisEnsayos clínicosDawoud et al. · The British journal of oral & maxillofacial surgery, 2022

Abstract

The commonest cause of microvascular free flap failure is thrombosis at the anastomosis. Pharmacological antithrombotic therapies have been used to mitigate this risk, but they carry the risk of bleeding and haematoma formation. To justify any intervention, it is necessary to evaluate the benefits and balance of risks. This meta-analysis aims to quantify the value of systemic anticoagulation during head and neck free tissue reconstruction. We performed a systematic review on the impact of additional prophylactic antithrombotic therapy on head and neck (H&N) free tissue transfer (on top and above the use of low molecular weight heparin to prevent deep vein thrombosis). We carried a PRISMA-guided literature review, following registration with PROSPERO. All studies analysing the possible impact of prophylactic anticoagulants on free flap surgery in the head and neck were eligible. The primary outcome was perioperative free flap complications (perioperative thrombosis, partial or total free flap failure, thrombo-embolic events, or re-exploration of anastomosis). Secondary outcomes included haematoma formation or bleeding complications requiring further intervention. We identified eight eligible studies out of 454. These included 3531 free flaps for H&N reconstruction. None of the assessed interventions demonstrated a statistically significant improvement in free flap outcomes. Accumulative analysis of all anti-coagulated groups demonstrated an increased relative risk of free flap complications [RR 1.54 (0.73-3.23)] compared to control albeit not statistically significant (p = 0.25). Pooled analysis from the included studies showed that the prophylactic use of therapeutic doses of anticoagulants significantly (p = 0.003) increased the risk of haematoma and bleeding requiring intervention [RR 2.98 (1.47-6.07)], without reducing the risk of free flap failure. Additional anticoagulation does not reduce the incidence of free flap thrombosis and failure. Unfractionated heparin (UFH) consistently increased the risk of free flap complications. The use of additional anticoagulation as 'prophylaxis' in the perioperative setting, increases the risk of haematoma and bleeding.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeMeta-AnalysisSystematic ReviewJournal Article
Indexed MeSH termsHumansHeparinFree Tissue FlapsAnticoagulantsHemorrhagePostoperative ComplicationsThrombosisHematoma

Resumen

The commonest cause of microvascular free flap failure is thrombosis at the anastomosis. Pharmacological antithrombotic therapies have been used to mitigate this risk, but they carry the risk of bleeding and haematoma formation.

Por qué esto importa para la hirudoterapia

Esta revisión sistemática y metanálisis investigó la eficacia y la seguridad de la anticoagulación sistémica sobre los desenlaces en la reconstrucción microquirúrgica con colgajos libres de cabeza y cuello, hallando que los anticoagulantes terapéuticos aumentaron significativamente el riesgo de hematoma y sangrado sin reducir la falla del colgajo. El análisis destaca específicamente el delicado equilibrio entre intentar prevenir la trombosis y las complicaciones hemorrágicas que pueden surgir con agentes farmacéuticos sistémicos como la heparina no fraccionada. No obstante, el resumen se centra por completo en la anticoagulación profiláctica sistémica y no menciona sanguijuelas, hirudoterapia ni el secretoma de sanguijuela. Por tanto, su relevancia para la American Society of Hirudotherapy es estrictamente indirecta, limitada únicamente a los riesgos generales de anticoagulación quirúrgica.

Citación

Does anticoagulation improve outcomes of microvascular free flap reconstruction following head and neck surgery: a systematic review and meta-analysis.

Dawoud et al. · The British journal of oral & maxillofacial surgery, 2022

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 28, 2026 · Última actualización del sitio: 18 de junio de 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.